Stocks Health care STTK
NASDAQ · Health careShattuck Labs, Inc. (STTK)
Shattuck Labs, Inc. brought in $0 of revenue over the twelve months to September 30, 2026, down 100.0% from a year earlier. It posted a net loss of $67.7M. In fiscal 2025 capital spending exceeded operating cash flow by $40M. At September 30, 2026 it held $61.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Shattuck Labs, Inc.
- Net worth
- Shattuck Labs, Inc. has a market value (market cap) of $501.8M at the latest share price, and shareholders' equity of $193.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1M (-82.5% year on year), with a net loss of $48.8M. Over the 12 months to September 30, 2026: revenue $0, net loss $67.7M.
- Cash flow
- In fiscal 2025 operations used $39.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Shattuck Labs, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Shattuck Labs, Inc. does
Shattuck Labs, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker STTK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1M | -$48.8M | -$0.70 | -$40M |
| 2024 | $5.7M | -$75.4M | -$1.49 | -$60.6M |
| 2023 | $1.7M | -$87.3M | -$2.05 | -$81.6M |
| 2022 | $652K | -$101.9M | -$2.41 | -$106.1M |
| 2021 | $30M | -$45M | -$1.07 | -$65M |
| 2020 | $9.9M | -$36.6M | -$2.36 | -$34.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where STTK ranks in Health care
Latest SEC filings
What Shattuck Labs, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 11, 2026
- July 17, 2026Activist stake changed SCHEDULE 13D/A
- June 17, 2026Passive stake (5% or more) SCHEDULE 13G
- June 15, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Shattuck Labs, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 6, 2026 | Shukla Abhinav A.Chief Technical Officer | Exercised options | 12,153 | $43.4K |
| July 2, 2026 | Shukla Abhinav A.Chief Technical Officer | Exercised options | 410 | $1.5K |
| July 2, 2026 | Shukla Abhinav A.Chief Technical Officer | Soldpre-planned (10b5-1) | 410 | $2.9K |
| July 1, 2026 | Shukla Abhinav A.Chief Technical Officer | Exercised options | 100 | $357 |
| July 1, 2026 | Shukla Abhinav A.Chief Technical Officer | Soldpre-planned (10b5-1) | 100 | $707 |
| June 30, 2026 | Pandite Arundathy N.Chief Medical Officer | Soldpre-planned (10b5-1) | 30,000 | $210.3K |
| June 30, 2026 | Shukla Abhinav A.Chief Technical Officer | Exercised options | 23,365 | $83.4K |
| June 30, 2026 | Shukla Abhinav A.Chief Technical Officer | Soldpre-planned (10b5-1) | 23,365 | $165.4K |
Who owns STTK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Investment Management, Inc.13G, passive | 15.3% | August 14, 2026 |
| Orbimed Advisors LLC13D, may seek influence with 2 related filers | 9.99% | June 15, 2026 |
| Prosight Management, LP13G, passive with 4 related filers | 9.9% | November 13, 2025 |
| Redmile Group, LLC13D, may seek influence with 2 related filers | 9.9% | July 17, 2026 |
| Adage Capital Management, L.P.13G, passive with 3 related filers | 9.79% | February 12, 2025 |
| BlackRock, Inc.13G, passive | 5.3% | October 27, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 5.17% | June 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 100 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 8,122,179 | +3,477,222 |
| Redmile Group, LLC | 6,892,033 | +1,352,309 |
| Orbimed Advisors LLC | 6,306,127 | 0 |
| Prosight Management, LP | 5,957,877 | +953,438 |
| BlackRock, Inc. | 3,935,810 | +3,425,004 |
| Frazier Life Sciences Management, L.P. | 3,750,000 | new |
| NEXTBio Capital Management LP | 3,727,348 | +577,441 |
| Deep Track Capital, LP | 3,706,734 | new |
| Vanguard Capital Management LLC | 3,207,865 | +930,689 |
| Pinnacle Associates Ltd | 1,871,442 | +503,219 |
| Wellington Management Group Llp | 1,767,938 | new |
| Geode Capital Management, LLC | 1,584,756 | +939,051 |
| Clark Estates Inc | 1,430,167 | -45,481 |
| Aberdeen Group plc | 1,405,851 | +246,530 |
| Point72 Asset Management, L.P. | 1,170,732 | +139,683 |
| 683 Capital Management, LLC | 1,157,216 | +357,216 |
| State Street Corp | 1,026,394 | +762,626 |
| Boxer Capital Management, LLC | 1,000,000 | new |
| Vanguard Portfolio Management LLC | 946,985 | new |
| Renaissance Technologies LLC | 743,761 | +139,261 |
Insiders
7 insiders reported holding 1,134,679 shares in total, about $5.7M at the last price.
| Holder | Shares |
|---|---|
| Siegall Clay BDirector | 318,608 |
| Neill Andrew RChief Financial Officer | 292,251 |
| Pandite Arundathy N.Chief Medical Officer | 136,219 |
| Schreiber TaylorChief Executive Officer, Director | 122,222 |
| Shukla Abhinav A.Chief Technical Officer | 98,533 |
| Stout StephenSee Remarks | 93,366 |
| DeYoung CasiChief Business Officer | 73,480 |
Questions about STTK
What does Shattuck Labs, Inc. do?
Shattuck Labs, Inc. is a company in the Health care sector, listed on NASDAQ as STTK. Its shares trade on NASDAQ under the ticker STTK.
What is Shattuck Labs, Inc.'s net worth?
Shattuck Labs, Inc. has a market value (market cap) of $501.8M at the latest share price, and shareholders' equity of $193.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Shattuck Labs, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $67.7M.
How much revenue does Shattuck Labs, Inc. make?
Over the twelve months to September 30, 2026 Shattuck Labs, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Shattuck Labs, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Shattuck Labs, Inc.'s next earnings report?
Shattuck Labs, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare STTK with
Follow STTK
Get an email when Shattuck Labs, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Shattuck Labs, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.